Biotech startup coupling at-home capillary blood collection with single-cell RNA sequencing to profile the human immune system at high resolution, licensing a patented platform from Caltech. It serves biopharma with patient stratification for trials and is building a consumer immune-insights product. ImYoo is an immune-profiling company rather than a psychedelic developer; it appears here as a portfolio holding of a psychedelic-focused venture fund.